Actively Recruiting
Chemotherapy Treatment Evaluation for Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Young Adults
Led by Dana-Farber Cancer Institute · Updated on 2026-08-17
67
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a chemotherapy regimen for adolescents and young adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia ALL. This Phase 2, single-arm study aims to better understand the safety and effectiveness of this treatment in this specific group. The study drugs include several chemotherapy agents and immunotherapy, all FDA-approved but studied here as a combined regimen. The treatment involves multiple phases such as Steroid Prophase, Induction IA and IB, several Blinatumomab cycles, and Consolidation and Continuation phases. These phases include administration of various drugs like dexamethasone, vincristine, pegaspargase, doxorubicin, cyclophosphamide, cytarabine, mercaptopurine, methotrexate, etoposide, and blinatumomab. Treatments are given in cycles lasting from 3 to 42 days, with intrathecal chemotherapy injections included. After about 2 years of treatment, participants will have an end of treatment visit followed by an 8-year follow-up period. Participants will undergo screening, in-clinic visits, and various tests including blood, urine, saliva tests, X-rays, ECGs, echocardiograms, DEXA scans, and bone marrow biopsiesaspirations. Researchers will monitor treatment completion, treatment-related mortality, toxicity rates, remission rates, measurable residual disease, survival outcomes, and transplantation rates. The entire participation is expected to last about 10 years, with close monitoring of adverse events and long-term outcomes.
CONDITIONS
Brief Title
ALL Backbone in AYAs
Research Team
M
Marlise R Luskin, MD, MSCE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here